The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...
In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has ...
The FTC’s recent action extends beyond Novo Nordisk, with warning letters sent to multiple pharmaceutical companies challenging the accuracy or relevance of over 300 patent listings across ...
The Federal Trade Commission said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs ...
The Federal Trade Commission (FTC) sent warning letters to 10 drugmakers, including Novo Nordisk (NVO), Teva Pharmaceutical (NYSE:TEVA), and AstraZeneca (NASDAQ:AZN), on Tuesday over questionable ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the ...
Shenzhen Honghongjing Trading Co. filed a patent infringement lawsuit on May 15 in Illinois Northern District Court. The lawsuit, filed by Stratum Law, targets unidentified e-commerce operators.
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the injectable ...